Hepatitis B Virus Reactivation Associated With Therapeutic Interventions.
Front Med (Lausanne)
; 8: 770124, 2021.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2065530
ABSTRACT
Hepatitis B virus (HBV) reactivation associated with various therapeutic interventions is an important cause of morbidity and mortality in patients with current or resolved HBV infection. Because no curative treatment for HBV infection is yet available, there are many individuals at risk for HBV reactivation in the general population. Populations at risk for HBV reactivation include patients who are currently infected with HBV or who have been exposed to HBV in the past. HBV reactivation and its potential consequences is a concern when these populations are exposed to anti-cancer chemotherapy, immunosuppressive or immunomodulatory therapies for the management of various malignancies, rheumatologic diseases, inflammatory bowel disease, or solid-organ or hematologic stem cell transplantation. Accordingly, it has become important to understand the basics of HBV reactivation and the mechanisms by which certain therapies are more susceptible to HBV reactivation. This review aims to raise the awareness of HBV reactivation and to understand the mechanisms and the risks of HBV reactivation in various clinical settings.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio experimental
/
Estudio pronóstico
Idioma:
Inglés
Revista:
Front Med (Lausanne)
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
Fmed.2021.770124
Similares
MEDLINE
...
LILACS
LIS